Marvel Biosciences to Give Oral Presentation at The Annual IRSF Rett Syndrome Scientific Meeting
Marvel Biosciences (TSXV: MRVL, OTCQB: MBCOF) has been selected to present at the International Rett Syndrome Foundation (IRSF) Scientific Meeting from June 9-11th, 2025. Dr. Mark Williams, Chief Science Officer, will present the company's latest preclinical studies of MB-204 in Rett Syndrome and Autism Spectrum Disorder (ASD).
The research was conducted in collaboration with Dr. Julie Le Merrer and Dr. Jérôme Becker from the iBraiN Institute in Tours, France, producing promising preclinical data. The company plans to publish full study results in a peer-reviewed journal and is preparing to submit an application for Orphan Drug Designation for MB-204 as a Rett syndrome treatment with the U.S. FDA.
Marvel Biosciences (TSXV: MRVL, OTCQB: MBCOF) è stata selezionata per presentare al International Rett Syndrome Foundation (IRSF) Scientific Meeting che si terrà dal 9 all'11 giugno 2025. Il Dott. Mark Williams, Chief Science Officer, presenterà gli ultimi studi preclinici dell'azienda su MB-204 nella Sindrome di Rett e nel Disturbo dello Spettro Autistico (ASD).
La ricerca è stata condotta in collaborazione con la Dott.ssa Julie Le Merrer e il Dott. Jérôme Becker dell'Istituto iBraiN di Tours, Francia, ottenendo dati preclinici promettenti. L'azienda prevede di pubblicare i risultati completi dello studio su una rivista scientifica peer-reviewed e sta preparando la domanda per la Designazione di Farmaco Orfano per MB-204 come trattamento per la Sindrome di Rett presso la FDA statunitense.
Marvel Biosciences (TSXV: MRVL, OTCQB: MBCOF) ha sido seleccionada para presentar en la Reunión Científica de la International Rett Syndrome Foundation (IRSF) del 9 al 11 de junio de 2025. El Dr. Mark Williams, Director Científico, presentará los últimos estudios preclínicos de la compañía sobre MB-204 en el Síndrome de Rett y el Trastorno del Espectro Autista (TEA).
La investigación se realizó en colaboración con la Dra. Julie Le Merrer y el Dr. Jérôme Becker del Instituto iBraiN en Tours, Francia, generando datos preclínicos prometedores. La compañía planea publicar los resultados completos del estudio en una revista científica revisada por pares y está preparando la solicitud para la Designación de Medicamento Huérfano para MB-204 como tratamiento para el síndrome de Rett ante la FDA de EE.UU.
Marvel Biosciences (TSXV: MRVL, OTCQB: MBCOF)는 2025년 6월 9일부터 11일까지 열리는 국제 레트 증후군 재단(IRSF) 과학 회의에서 발표할 기회를 얻었습니다. 마크 윌리엄스 박사 최고 과학 책임자가 레트 증후군과 자폐 스펙트럼 장애(ASD)에 대한 회사의 최신 전임상 연구 MB-204를 발표할 예정입니다.
이 연구는 프랑스 투르에 위치한 iBraiN 연구소의 줄리 르 메레 박사와 제롬 베커 박사와 협력하여 수행되었으며, 유망한 전임상 데이터를 도출했습니다. 회사는 동료 심사 저널에 전체 연구 결과를 출판할 계획이며, 미국 FDA에 레트 증후군 치료제로서 희귀 의약품 지정 신청을 준비 중입니다.
Marvel Biosciences (TSXV : MRVL, OTCQB : MBCOF) a été sélectionnée pour présenter lors de la Réunion Scientifique de la International Rett Syndrome Foundation (IRSF) du 9 au 11 juin 2025. Le Dr Mark Williams, directeur scientifique, présentera les dernières études précliniques de la société sur MB-204 dans la sclérose du syndrome de Rett et le trouble du spectre autistique (TSA).
La recherche a été menée en collaboration avec le Dr Julie Le Merrer et le Dr Jérôme Becker de l'institut iBraiN à Tours, France, produisant des données précliniques prometteuses. La société prévoit de publier les résultats complets de l'étude dans une revue scientifique à comité de lecture et prépare une demande de Désignation de Médicament Orphelin pour MB-204 en tant que traitement du syndrome de Rett auprès de la FDA américaine.
Marvel Biosciences (TSXV: MRVL, OTCQB: MBCOF) wurde ausgewählt, auf dem International Rett Syndrome Foundation (IRSF) Scientific Meeting vom 9. bis 11. Juni 2025 zu präsentieren. Dr. Mark Williams, Chief Science Officer, wird die neuesten präklinischen Studien des Unternehmens zu MB-204 bei Rett-Syndrom und Autismus-Spektrum-Störung (ASD) vorstellen.
Die Forschung wurde in Zusammenarbeit mit Dr. Julie Le Merrer und Dr. Jérôme Becker vom iBraiN-Institut in Tours, Frankreich, durchgeführt und lieferte vielversprechende präklinische Daten. Das Unternehmen plant, die vollständigen Studienergebnisse in einer peer-reviewten Fachzeitschrift zu veröffentlichen und bereitet die Einreichung eines Antrags auf Orphan-Drug-Status für MB-204 als Behandlung des Rett-Syndroms bei der US-amerikanischen FDA vor.
- Promising preclinical data for MB-204 in Rett Syndrome and ASD
- Pursuing Orphan Drug Designation with FDA for MB-204
- None.
Calgary, Alberta--(Newsfile Corp. - April 16, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (together "Marvel"), are pleased to announce their acceptance to give an oral presention at the International Rett Syndrome Foundation (IRSF) Scientific Meeting, taking place June 9-11th, 2025.
Dr. Mark Williams, Chief Science Officer of Marvel, will present on behalf of the Company and its research collaborators, Dr. Julie Le Merrer and Dr. Jérôme Becker from the iBraiN Institute in Tours, France. The presentation will highlight Marvel's most recent preclinical studies of MB-204 in Rett Syndrome and Autism Spectrum Disorder (ASD). Drs. Le Merrer and Becker are leading experts in in vivo models of neuropsychiatric disorders, and their collaboration with Marvel has produced promising preclinical data for MB-204.
The IRSF Rett Syndrome Scientific Meeting is a premier international forum for the latest advancements in Rett research, connecting scientists, clinicians, and patient advocates working to accelerate the development of effective treatments. Hosted by the International Rett Syndrome Foundation, the event promotes collaboration and the translation of breakthrough research into clinical solutions.
"We are honored to present at the IRSF Rett Syndrome Scientific Meeting—one of the most important gatherings for advancing treatment and research in Rett Syndrome," said Dr. Mark Williams, Chief Science Officer of Marvel. "We're grateful to our collaborators for their partnership and look forward to sharing these compelling findings with the community."
"Our team is committed to delivering innovative therapies to address unmet needs in neurological and neurodevelopmental disorders," added Rod Matheson, CEO of Marvel. "We look forward to building new relationships at this meeting and advancing MB-204 toward clinical trials."
Marvel and its collaborators intend to publish the full study results in a peer-reviewed scientific journal. In parallel, Marvel is preparing to submit an application for Orphan Drug Designation for MB-204 as a treatment for Rett syndrome with the U.S. FDA.
About Marvel Biosciences Corp.
Marvel Biosciences Corp., and its wholly owned subsidiary, Marvel Biotechnology Inc., is a Calgary- based pre-clinical stage pharmaceutical development biotechnology company. The Company is developing MB-204, a novel fluorinated derivative of the approved anti-Parkinson's drug Istradefylline, the only clinically approved adenosine A2a antagonist. A significant and growing body of scientific evidence suggests drugs that block the adenosine A2a receptor, such as MB-204, could be useful in treating other neurological diseases such as autism, depression and Alzheimer's Disease. The Company is actively investigating its potential in addressing other neurodevelopmental disorders, such as Rett Syndrome and Fragile X Syndrome, to expand its therapeutic reach.
Contact Information:
Marvel Biosciences Corp.
J. Roderick (Rod) Matheson, Chief Executive Officer or
Dr. Mark Williams, President and Chief Science Officer Tel: 403 770 2469
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release. All information contained in this news release with respect to the Company and its subsidiary,(collectively, the "Parties") were supplied by Marvel, respectively, for inclusion herein and each parties' directors and officers have relied on each other for any information concerning such Party.
This news release may contain forward-looking statements and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of the Company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the expectations of the Company and include other risks detailed from time to time in the filings made by the Company under securities regulations.
The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. As a result, the Company cannot guarantee that the above events on the terms will occur and within the time disclosed herein or at all. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by Canadian securities law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/248637
FAQ
What will Marvel Biosciences (MBCOF) present at the 2025 IRSF Scientific Meeting?
When is Marvel Biosciences (MBCOF) presenting at the IRSF Scientific Meeting?
What are Marvel Biosciences' (MBCOF) plans for MB-204 drug development?
Who are Marvel Biosciences' (MBCOF) research collaborators for the MB-204 studies?
